Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé

Robert Bm Landewé; Juergen Braun

doi:https://doi.org/10.1136/annrheumdis-2022-222359

Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé

Research output: Contribution to journal › Comment/Letter to the editor › Academic

2 Citations (Scopus)

Original language	English
Article number	annrheumdis-2022-222359
Journal	Annals of the rheumatic diseases
Early online date	2022
DOIs	https://doi.org/10.1136/annrheumdis-2022-222359
Publication status	E-pub ahead of print - 2022

Keywords

Arthritis, Psoriatic
Fibromyalgia
Inflammation

Access to Document

https://doi.org/10.1136/annrheumdis-2022-222359

Cite this

Landewé, R. B., & Braun, J. (2022). Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé. Annals of the rheumatic diseases, Article annrheumdis-2022-222359. Advance online publication. https://doi.org/10.1136/annrheumdis-2022-222359

@article{ad8986da402e4c8798fbc0fd0546a3bd,

title = "Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landew{\'e}",

keywords = "Arthritis, Psoriatic, Fibromyalgia, Inflammation",

author = "Landew{\'e}, {Robert Bm} and Juergen Braun",

year = "2022",

doi = "https://doi.org/10.1136/annrheumdis-2022-222359",

language = "English",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

}

Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé. / Landewé, Robert Bm; Braun, Juergen.
In: Annals of the rheumatic diseases, 2022.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Response to

T2 - Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé

AU - Landewé, Robert Bm

AU - Braun, Juergen

PY - 2022

Y1 - 2022

KW - Arthritis, Psoriatic

KW - Fibromyalgia

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85130770765&partnerID=8YFLogxK

U2 - https://doi.org/10.1136/annrheumdis-2022-222359

DO - https://doi.org/10.1136/annrheumdis-2022-222359

M3 - Comment/Letter to the editor

C2 - 35487678

SN - 0003-4967

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

M1 - annrheumdis-2022-222359

ER -

Landewé RB, Braun J. Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé. Annals of the rheumatic diseases. 2022;annrheumdis-2022-222359. Epub 2022. doi: https://doi.org/10.1136/annrheumdis-2022-222359

Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé

Keywords

Access to Document

Other files and links

Cite this